The supply of the circuit boards needed to fix the devices is significantly constrained, preventing the company from ...

The FDA issued an early alert warning customers of potential issues with certain Resmed (NYSE:RMD) ventilator systems.

Selling the software business to Frazier Healthcare Partners will allow the respiratory device maker to shift more resources ...

July 7 (Reuters) - ResMed said on Tuesday it would sell its software business MatrixCare to private equity firm Frazier Healthcare Partners for $490 million in cash, as the health technology company ...

ResMed (RMD) stock faces a downgrade at RBC Capital Markets due to potential challenges the company is set to face in FY27.

The medical device maker has sold the MatrixCare business for less than it bought it eight years ago, with analysts pointing ...

Resmed has issued a voluntary Global Medicare Device Correction / Field Safety Notice for its Astral 100 and Astral 150 ventilators built prior to October 2024. At issue: The vents may stop delivering ...

ResMed is selling its MatrixCare home-health software unit to Frazier Healthcare Partners for $490m in cash to focus on sleep and breathing care.

Resmed RMD has entered into a definitive agreement to sell its MatrixCare business to private equity firm Frazier Healthcare ...

Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its ...

ResMed Inc (ASX: RMD) announces sale of MatrixCare for $490m, plans capital return, and reaffirms FY26 guidance.

ResMed (RMD) stock is currently at a fascinating juncture. It is trading at a low price, and if you decide to invest in it, you are wagering on a company that is demonstrating reasonable growth, ...